首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   19523篇
  免费   1858篇
  国内免费   1209篇
耳鼻咽喉   187篇
儿科学   274篇
妇产科学   240篇
基础医学   2210篇
口腔科学   390篇
临床医学   2477篇
内科学   2786篇
皮肤病学   228篇
神经病学   962篇
特种医学   662篇
外国民族医学   3篇
外科学   2086篇
综合类   3452篇
现状与发展   4篇
一般理论   6篇
预防医学   1508篇
眼科学   502篇
药学   1822篇
  23篇
中国医学   1265篇
肿瘤学   1503篇
  2024年   52篇
  2023年   284篇
  2022年   557篇
  2021年   980篇
  2020年   736篇
  2019年   587篇
  2018年   652篇
  2017年   562篇
  2016年   538篇
  2015年   779篇
  2014年   882篇
  2013年   994篇
  2012年   1448篇
  2011年   1503篇
  2010年   1080篇
  2009年   938篇
  2008年   1190篇
  2007年   1169篇
  2006年   1134篇
  2005年   986篇
  2004年   772篇
  2003年   754篇
  2002年   660篇
  2001年   500篇
  2000年   515篇
  1999年   416篇
  1998年   253篇
  1997年   213篇
  1996年   170篇
  1995年   189篇
  1994年   143篇
  1993年   79篇
  1992年   132篇
  1991年   110篇
  1990年   84篇
  1989年   71篇
  1988年   76篇
  1987年   64篇
  1986年   52篇
  1985年   44篇
  1984年   36篇
  1983年   24篇
  1982年   18篇
  1981年   15篇
  1980年   18篇
  1979年   31篇
  1977年   16篇
  1973年   11篇
  1972年   10篇
  1971年   9篇
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
21.
张彤  杨镇 《临床外科杂志》2006,14(7):417-419
目的探讨压力增高对血管内皮细胞分泌血管活性物质功能的影响及其在门静脉高压症发病机制中的作用。方法用RT-PCR方法半定量研究人脐静脉内皮细胞ET-1、eNOS、i-NOS mRNA的表达;用硝酸还原酶法检测各组细胞培养液中NO代谢产物NO2-/NO3-的含量,免疫荧光标记激光扫描共聚焦显微镜检测培养细胞的ET-1蛋白表达。结果ET-1和eNOS mR-NA在正常培养的内皮细胞中即有表达,iNOS mRNA则几乎无表达。生理水平压力刺激下各组各待测基因mRNA表达与对照组无显著性差异。超生理范围压力刺激后,ET-1 mRNA有显著性升高。eNOS mRNA在40 mm Hg 24 h后才有显著性差异。iNOS mRNA在不同条件下均无显著变化。在细胞培养液中分别加入细胞外钙螯合剂EGTA、PKC抑制剂后,则见ET-1、eNOS mRNA表达下降。结论压力增高可刺激血管内皮细胞合成ET-1、NO,其作用在转录水平,其作用机制分别与PKC信号通路和细胞外钙浓度有关。门静脉压力增高与血管内皮细胞合成ET-1、NO增多之间存在相互作用。  相似文献   
22.
笔者从2000年1月~2005年6月,采用针灸配合中西药治疗脑梗死恢复期30例,疗效显著,现报告如下。一般资料60例均为我科住院患者,其诊断均经颅脑CT或MRI确诊。治疗组30例,男21例,女9例;年龄在45~76岁,平均65岁;病程7~15天;肢体肌力0~2级。对照组30例,男22例,女8例;年龄46~75岁,平均60岁;病程7~15天;肢体肌力0~2级。两组资料比较,无显著性差异(P>0.05),具有可比性。治疗方法对照组:给予抗凝、抗血小板聚集,改善脑循环、脑保护及对症治疗。静点5%葡萄糖注射液250ml 血塞通500mg;静点5%葡萄糖注射液250ml 维生素C2.0g 胞二磷胆碱0.75g。治疗组在…  相似文献   
23.
24.
目的 了解小儿烧伤的致伤因素和院前急救现状。方法 对十年来两家医院收治的小儿烧伤1403例按年龄、原因、场所以及院前急救进行回顾性分析。结果 小儿烧伤以0~3岁居多(占57.09%);热液烫伤比例大(占70.28%);家庭为烧伤主要场所(占78.12%);院前急救失误普通存在,其中创面处理不当、未建立有效静脉通道和人为原因延误治疗比例较大。结论 小儿烧伤有一定规律,院前急救应加以重视。  相似文献   
25.
PGA指数和透明质酸在诊断慢性乙肝肝纤维化中的价值   总被引:1,自引:0,他引:1  
目的:寻找一种简便实用的诊断慢性乙型肝炎纤维化的方法。方法:以78例经肝穿刺病理证实的慢性乙型肝炎为对象,测定并比较了由PT、GGT、ApoA1组成的PGA指数和HA、LN、PⅢP、C-IV与肝内纤维化程度(S)和炎症活动度(G)的关系。结果:(1)LN、PⅢP、C-IV在轻度慢性乙肝时无明显升高,在中度慢性乙肝时明显高于正常,但与轻度慢性乙肝无差异,而PGA指数和HA不仅在轻度慢性乙肝时显著升高,而且在轻中度间差异明显.因重度慢性乙肝和活动性肝硬化时,五项指标均显著增高。(2)在G2-4期,HA、LN、PⅢP、C-IV均明显高升,但在G1期,只有PGA指数高于正常,且各期间差异显著。(3)在S1-2期,只有PGA指数、HA、C-IV明显上升,但C-IV的上升幅度远低于PGA指数和HA。(4)加以PGA>4.5或HA>200μg/L作为判断临界值,则两者判断肝纤维化的敏感性均>94%,精确性>91%,特异性>86%,如两者结合,则分别达到98.3%、95.2%和96.4%。结论:PGA指数和HA均是反映慢性乙型肝炎患者肝内纤维化程度的良好指标,两者联合检测则可达到最大的价值效益比。  相似文献   
26.
保留肾单位手术治疗早期小肾癌21例临床分析   总被引:1,自引:0,他引:1  
OBJECTIVE: To evaluate the clinical effects of nephron-sparing surgery in patients with early-stage small renal cell carcinoma. METHODS: Nephron-sparing surgery was performed in 21 patients with renal cell carcinoma including 1 with solitary kidney, 3 with unilateral tumor and contralateral renal compromise, and 17 with unilateral tumor and normal contralateral kidney. The diameter of the tumors ranged from 1.5 to 6.0 cm, with a mean of 2.8 cm. The tumor diameter in 17 patients with normal contralateral kidney was less than 4 cm (mean 2.5 cm) and the average diameter in 4 patients with contralateral renal compromise was 4.2 cm. Sixteen cases were in stage T(1), 4 in stage T(2), and 1 in stage T(3). Of the 21 patients, 4 underwent tumor enucleation, 10 polar nephrectomy and 7 wedge resection. RESULTS: All patients were followed up for an average of 40.8 months (7 to 66 months). One patient suffered a right lung and mediastinum metastasis 3 years after the surgery later and 1 with chronic glomerulonephritis required dialysis 27 months after the operation. No surgical complication or local recurrence were found in other patients. CONCLUSION: As a safe and effective therapy for early-stage small renal cell carcinoma, nephron-sparing surgery can be considered as the gold-standard therapy for patients with lesions less than 4 cm in T(1) and T(2) stages of localized unilateral tumor with normal contralateral kidney.  相似文献   
27.
28.
Background: The Rhinitis Symptom Utility Index (RSUI), originally developed in the United States, consists of a patient-preference weighting scheme and a 10-item questionnaire measuring the severity and frequency of rhinitis related symptoms over a 14-day period. This study aimed to determine whether the Chinese RSUI could adopt the US-based multi-attribute utility function (MAUF) in scoring rhinitis symptoms. Methods: In a Hong Kong study, 116 Chinese adults with allergic rhinitis completed the RSUI questionnaire and 36-item Short-Form Health Survey (SF-36) after they had been seen by two otorhinolaryngologists for disease-severity ratings. Respondents then completed computer-administered direct preference measures, i.e., visual analogue scale (VAS) and standard gamble (SG) assessments. The VAS and SG data were used to estimate a MAUF for the Chinese-based RSUI. Results: The derived MAUF was somewhat different than the one developed for the US RSUI. Test–retest reliability for the Chinese RSUI was satisfactory (ICC = 0.71, p<0.001). Scores differentiated among cases with mild, moderate, and severe symptoms (p<0.001); and between those who did and did not require medications to control symptoms (p = 0.031). Findings were significantly correlated with SF-36 domain scores (r = 0.19 to 0.37; p=0.041 to <0.001). When the US-based scoring function was applied to the Chinese subjects, the resulting mean RSUI score was significantly lower (p<0.001). Comparisons between directly measured VAS and SG scores between the US and Chinese samples, demonstrated significant differences (all p<0.05), with the US subjects consistently rating rhinitis symptoms as worse than Chinese subjects. Conclusions: The Chinese RSUI has good measurement properties that reflect patient preferences from the Chinese. Results suggest that there are differences in preference rating between US and Chinese subjects and that use of the US-based preference function for the RSUI would bias the measurement of rhinitis symptom outcomes in Chinese subjects.  相似文献   
29.
Phytochemical-mediated modulation of P-glycoprotein (P-gp) and other drug transporters may give rise to many herb-drug interactions. Serial plasma concentration-time profiles of the P-gp substrate, digoxin, were used to determine whether supplementation with goldenseal or kava kava modified P-gp activity in vivo. Twenty healthy volunteers were randomly assigned to receive a standardized goldenseal (3210 mg daily) or kava kava (1227 mg daily) supplement for 14 days, followed by a 30-day washout period. Subjects were also randomized to receive rifampin (600 mg daily, 7 days) and clarithromycin (1000 mg daily, 7 days) as positive controls for P-gp induction and inhibition, respectively. Digoxin (Lanoxin, 0.5 mg) was administered p.o. before and at the end of each supplementation and control period. Serial digoxin plasma concentrations were obtained over 24 h and analyzed by chemiluminescent immunoassay. Comparisons of area under the curve (AUC)((0-3)), AUC((0-24)), C(max,) CL/F, and elimination half-life were used to assess the effects of goldenseal, kava kava, rifampin, and clarithromycin on digoxin pharmacokinetics. Rifampin produced significant reductions (p < 0.01) in AUC((0-3)), AUC((0-24)), CL/F, t(1/2), and C(max), whereas clarithromycin increased these parameters significantly (p < 0.01). With the exception of goldenseal's effect on C(max) (14% increase), no statistically significant effects on digoxin pharmacokinetics were observed following supplementation with either goldenseal or kava kava. When compared with rifampin and clarithromycin, supplementation with these specific formulations of goldenseal or kava kava did not appear to affect digoxin pharmacokinetics, suggesting that these supplements are not potent modulators of P-gp in vivo.  相似文献   
30.
便秘是老年糖尿病患者的常见合并症之一.笔者自2006年6月~2007年6月以济川煎为基础方加味治疗老年糖尿病患者合并便秘24例,现报道如下.   ……  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号